Human Mouse Rat
Amyloid Precursor Protein (APP, UniProt Accession Number P05067) is a 770 amino acid, single-pass transmembrane protein whose beta-amyloid proteolytic fragment can form neurotoxic extracellular accumulations in human cerebral cortex, and is widely believed to be the cause of Alzheimer's dementia. However, the normal function of APP itself is still obscure, as are potential functions of various proteolytic fragments that have been observed in human brain [Muller, U.C., Deller, T., Korte, M. (2017) Nature Reviews Neuroscience 18: 281-298)]. To better understand these functions, we have made a set of five anti-peptide antibody reagents against APP. One of the peptide sequences used is within the beta-amyloid fragment and recognizes the extracellular amyloid plaques observed in Alzheimer's patients' brains (see Cat.# ABN). Three other peptide sequences used, however, are within the extracellular domain of APP outside of this domain, and are useful for identifying the APP protein itself, and various proteolytic fragments, rather than the beta-amyloid peptide and plaques.
Chickens were immunized with a keyhole limpet hemocyanin (KLH) conjugate of the synthetic peptide EEI QDE VDE LLQ KEQ NYS DD, which corresponds to residues #556-575 of the human gene product (NP_000475.1). This sequence is also conserved in the mouse and rat APP gene products, as well. After repeated injections, immune eggs were collected from the hens, and the IgY fractions were purified from the yolks. These IgY fractions were then affinity-purified against the cognate peptide using an agarose column, the concentration of the eluates adjusted to 100 µg/mL, and the preparation was filter-sterilized.
Amyloid-beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Amyloid precursor protein) (Amyloid-beta precursor protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99 (Beta-secretase C-terminal fragment) (Beta-CTF); Amyloid-beta protein 42 (Abeta42) (Beta-APP42); Amyloid-beta protein 40 (Abeta40) (Beta-APP40); C83 (Alpha-secretase C-terminal fragment) (Alpha-CTF); P3(42); P3(40); C80; Gamma-secretase C-terminal fragment 59 (Amyloid intracellular domain 59) (AICD-59) (AID(59)) (Gamma-CTF(59)); Gamma-secretase C-terminal fragment 57 (Amyloid intracellular domain 57) (AICD-57) (AID(57)) (Gamma-CTF(57)); Gamma-secretase C-terminal fragment 50 (Amyloid intracellular domain 50) (AICD-50) (AID(50)) (Gamma-CTF(50)); C31]
APP A4 AD1
Antibody Validation and Application Notes
This antibody has been validated using the following assays:
The following quality control assay is performed on each new lot of this antibody to ensure it meets designated performance requirements.
This anti-peptide antibody mixture was analyzed by immunohistochemistry (at a dilution of 1:1000) using fluorescein-labeled goat anti-chicken IgY (1:500 dilution, Aves Labs Cat.# F-1005) as the secondary reagent.